AbbVie doubles down on cancer project with biotech group Argenx

Biotech group Argenx (ARGX.BR) said on Wednesday U.S. pharma group AbbVie (ABBV.N) had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million(490.08 million pounds).